Lori Westendorf

4PUBLICATIONS

63CO-AUTHORS

Molecular targetsPredictive and prognostic markersGlycoconjugates

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (4)

Sort by Publication Date:

|Jul 28, 2026

PF-08046876, a differentiated integrin beta-6 antibody-drug conjugate delivering a potent camptothecin payload optimized for bystander effect and reduced drug efflux.

|Oct 28, 2024

Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47.

Matthew R Levengood, Christopher M Carosino, Xinqun Zhang

|Aug 24, 2023

SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.

Robert P Lyon, Mechthild Jonas, Christopher Frantz

|Feb 17, 2023

SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.

Rebecca Mazahreh, Marsha L Mason, John J Gosink

Pageof 1

Frequent Collaborators

Rebecca Mazahreh

Vivian H Trang

Devra J Olson

Christopher J Hale

Narayana Yeddula

Kelly M Hensley

Roma Yumul

Marsha L Mason

Robert Thurman

Christopher I Leiske

Frequent Collaborators

Rebecca Mazahreh

Vivian H Trang

Devra J Olson

Christopher J Hale